Results 131 to 140 of about 21,074 (263)

Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control. [PDF]

Cureus
Hemdev V, Abuzenah M, Alsaafin Q, Al Ghananeem Z, Diksha F, Khatak A.   +5 more
europepmc   +1 more source

SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review. [PDF]

Eur J Clin Pharmacol
Cruz AM, Lima BCV, de Ferreira JESM, Teles RB.   +3 more
europepmc   +1 more source

MAFLD/MASLD: Past, Present, and Future

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD), also known as nonalcoholic fatty liver disease and metabolic dysfunction‐associated fatty liver disease, affects more than 30% of the global adult population and has become one of the leading causes of cirrhosis and hepatocellular carcinoma.
Vincent Wai‐Sun Wong
wiley   +1 more source

Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study. [PDF]

Front Endocrinol (Lausanne)
Kapan A, Moser O, Felsinger R, Waldhoer T.   +3 more
europepmc   +1 more source

The ciliary neurotrophic factor induces Stat3 phosphorylation in distinctive cytotypes of organs involved in body metabolism: An immunohistochemical study

Journal of Anatomy, EarlyView.
p‐STAT3‐positive cells in metabolically relevant peripheral organs and tissues from mice administered with recombinant CNTF (0.3 mg/kg). Abstract Administration of ciliary neurotrophic factor (CNTF) reduces food intake and body weight in both humans and experimental animals, where it also ameliorates hyperglycemia, hyperinsulinemia, and dyslipidemia ...
Chiara Galli, Georgia Colleluori, Jessica Perugini, Edoardo Scopini, Ilenia Severi, Gaia Grandin, Antonio Giordano   +6 more
wiley   +1 more source

Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States

Diabetes, Metabolic Syndrome and Obesity
Sriya Amruta Kosaraju,1 Rong M Zhang2 1Department of Biomedical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA; 2Department of Medicine-Division of Endocrinology, Washington University, St Louis, MO, USACorrespondence: Rong M Zhang ...
Kosaraju SA, Zhang RM
doaj  

GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. [PDF]

Diabetes Metab Syndr Obes
Abid M, Sheikh KS, Ahmad MS, Jiang H.
europepmc   +1 more source

EffectS of Lifestyle Interventions in Older PEople With Obesity (Effective SLOPE): a Systematic Review With Network Meta‐Analyses

Obesity Reviews, EarlyView.
ABSTRACT Background/Aim We conducted a systematic review with network meta‐analyses (NMA) summarizing the effects and safety of lifestyle interventions containing nutrition (NUT; e.g., calorie restriction), exercise (EX; e.g., aerobic/resistance exercise) and behavior change interventions (BCI; e.g., behavioral therapy) on physical function, body ...
Gabriel Torbahn, Daniel Schoene, Isabel Galicia Ernst, Lukas Schwingshackl, Gerta Rücker, Helge Knüttel, Wolfgang Kemmler, Cornel C. Sieber, John A. Batsis, Dennis T. Villareal, Nanette Stroebele‐Benschop, Dorothee Volkert, Eva Kiesswetter   +12 more
wiley   +1 more source

More than a sidekick: GIP signalling and cardiovascular outcomes. [PDF]

Eur Heart J
Kurt B, Kahles F.
europepmc   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source